/
BIVI
$2.01+$0.07 (+3.61%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$14.6M
8M shares
52-week range
$1.06 – $10.30
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
4.40%
Moderate
Price (6 mo)
Loading chart…
Change$-1642.99
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $229.4K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$229.4K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $370.9K | $1.0M | $1.2M | $133.2M | $17.3M | $33.3M | $23.1M | $9.3M |
| Operating income | −$2.4M | −$2.5M | −$2.7M | −$138.1M | −$27.3M | −$45.1M | −$32.2M | −$18.1M |
| EBITDA | −$2.1M | −$2.3M | −$2.5M | −$129.5M | −$23.7M | −$45.7M | −$29.0M | −$17.0M |
| Net income | −$2.4M | −$2.4M | −$16.7M | −$130.2M | −$26.1M | −$50.3M | −$32.1M | −$17.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -317.70 | -98.20 | -685.20 | -1482.30 | -106.00 | -154.70 | -73.05 | -12.12 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-2.95 | $-2.95–$-2.95 | 1 |
| 2027 | $368M | $433.00 | $433.00–$433.00 | 1 |
| 2028 | $0 | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$12.86
Price
$2.01
Implied upside
+540%
Peer comparison
BioVie, Inc. Common Stock
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
www.bioviepharma.com- Employees
- 13
- IPO / List date
- Jan 14, 2014
- HQ
- CARSON CITY, NV
Held by traders on TradeandTell
No one on the platform currently holds BIVI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 67,918 | $95.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-07-07 | 1-for-10reverse |
| 2024-08-06 | 1-for-10reverse |
| 2019-11-22 | 1-for-125reverse |
Recent trades on TradeandTell
No one on the platform has traded BIVI yet.
